Evidence map›Paper›PMID 39335505›Full record

ArticleBiomedicines2024

Metabolic-Associated Fatty Liver Disease and Cognitive Performance in Type 2 Diabetes: Basal Data from the Phytate, Neurodegeneration and Diabetes (PHYND) Study.

Antelm Pujol, Pilar Sanchis, María I Tamayo, Samantha Godoy, Paula Calvó, Asier Olmos, Pilar Andrés, Aleksandra Speranskaya, Ana Espino, Ana Estremera and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Liver, ageing and disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Antelm PujolVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-4579-4620
Pilar SanchisVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0001-8565-1811
María I TamayoVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Samantha GodoyVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Paula CalvóLaboratory of Renal Lithiasis Research, University of Balearic Islands, Research Institute of Heath Science (IUNICS), Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Asier OlmosNeuropsychology and Cognition, Department of Psychology, Research Institute of Heath Science (IUNICS), University of Balearic Islands, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Pilar AndrésNeuropsychology and Cognition, Department of Psychology, Research Institute of Heath Science (IUNICS), University of Balearic Islands, Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Aleksandra SperanskayaVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Ana EspinoNeurology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
Ana EstremeraNeuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
Elena RigoBalearic Research Group on Genetic Cardiopathies, Sudden Death, and TTR Amyloidosis, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.
Guillermo J AmengualNeuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
Manuel RodríguezNeuroradiology Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
José Luis RibesClinical Analysis Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
Isabel GomilaClinical Analysis Department, Son Llàtzer University Hospital, 07198 Palma de Mallorca, Spain.
Félix GrasesLaboratory of Renal Lithiasis Research, University of Balearic Islands, Research Institute of Heath Science (IUNICS), Health Research Institute of Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0001-5636-9139
Marta González-FreireTranslational Research in Aging and Longevity (TRIAL) Group, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0001-9741-2826
Lluís MasmiquelVascular and Metabolic Diseases Research Group, Endocrinology Department, Son Llàtzer University Hospital, Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain.ORCID 0000-0002-6549-5652

Funding

Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa) G-57326324Instituto de Salud Carlos III PI20/0471
6 · The paper itself

Abstract

The effect of liver fibrosis on mild cognitive impairment (MCI) and dementia risk in type 2 diabetes mellitus (T2DM) patients is unclear. Therefore, we performed a prospective cross-sectional study on 219 patients with T2DM and older than 60 years to evaluate the association between liver fibrosis, liver steatosis, and cognitive impairment. The Montreal Cognitive Assessment (MoCA) was used to screen for MCI or dementia. Liver fibrosis was estimated using the non-invasive Fibrosis-4 (FIB-4) score, and liver steatosis was assessed with the hepatic steatosis index. The mean age was 71 ± 6 years, 47% were women and according to MoCA cut-off values, 53.88% had MCI and 16.43% had dementia. A moderate or high risk of advanced fibrosis was significantly higher in patients with MCI or dementia compared to those with normal cognition (

Indexed as

cognitive impairmentcognitive performanceliver fibrosismetabolic-associated fatty liver diseasetype 2 diabetes mellitus

Identifiers

PMID39335505
PMCPMC11428552

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.